NOBILI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.073
EU - Europa 7.338
AS - Asia 1.531
OC - Oceania 106
AF - Africa 42
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 18.097
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.040
PL - Polonia 2.737
RU - Federazione Russa 2.057
IT - Italia 779
IE - Irlanda 672
SE - Svezia 465
SG - Singapore 454
HK - Hong Kong 382
CN - Cina 296
DE - Germania 173
JO - Giordania 116
FI - Finlandia 113
IN - India 111
AU - Australia 104
GB - Regno Unito 104
UA - Ucraina 76
TR - Turchia 50
VN - Vietnam 48
ID - Indonesia 43
CH - Svizzera 35
CI - Costa d'Avorio 33
AT - Austria 26
BE - Belgio 25
FR - Francia 24
CA - Canada 22
KR - Corea 19
NL - Olanda 19
ES - Italia 17
MX - Messico 8
IR - Iran 5
BR - Brasile 4
SC - Seychelles 4
AL - Albania 3
DK - Danimarca 3
GR - Grecia 3
BT - Bhutan 2
LT - Lituania 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
TN - Tunisia 2
AR - Argentina 1
CZ - Repubblica Ceca 1
EG - Egitto 1
EU - Europa 1
IL - Israele 1
JP - Giappone 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
RO - Romania 1
TH - Thailandia 1
TW - Taiwan 1
Totale 18.097
Salva come PNG Salva come JPEG
Città #
Warsaw 2.728
Santa Clara 2.399
Fairfield 884
Dublin 670
Chandler 669
Ashburn 484
Woodbridge 433
Cambridge 385
Seattle 377
Singapore 374
Houston 366
Wilmington 317
Ann Arbor 224
Hong Kong 222
Altamura 179
Princeton 173
Lawrence 168
Florence 134
Jacksonville 126
Boston 120
Beijing 104
Melbourne 102
Moscow 95
Mumbai 93
Boardman 86
Buffalo 82
Shanghai 71
Medford 68
Bremen 63
San Diego 60
Falls Church 47
Jakarta 42
Kent 41
Izmir 36
Bern 34
Abidjan 33
New York 33
Dong Ket 32
Norwalk 31
Dearborn 30
Rome 28
Vienna 25
Brussels 22
Hillsboro 22
Phoenix 21
London 20
Los Angeles 17
Toronto 17
West Jordan 16
Barcelona 15
Palermo 14
Andover 12
Milan 12
Helsinki 11
Pune 11
Redmond 11
Catania 10
Guangzhou 10
Bari 9
Yubileyny 9
Bologna 8
Guadalajara 8
Seongnam 8
Auburn Hills 7
Laurel 7
Tappahannock 7
Council Bluffs 6
Kunming 6
Seoul 6
Turin 6
Washington 6
Fiesole 5
Frankfurt Am Main 5
Kilburn 5
Modena 5
Biella 4
Cagliari 4
Lastra a Signa 4
Livorno 4
Monastir 4
Perugia 4
Philadelphia 4
Redwood City 4
Renton 4
Romainville 4
Shenzhen 4
Trumbull 4
Athens 3
Brasília 3
Castelliri 3
Coreno Ausonio 3
Frankfurt am Main 3
Genoa 3
Istres 3
Lanciano 3
Latina 3
Leawood 3
Munich 3
Naaldwijk 3
Nanjing 3
Totale 13.109
Salva come PNG Salva come JPEG
Nome #
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 299
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 290
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 290
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 287
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 286
Emerging drugs in refractory colorectal cancer 276
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 275
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 261
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 260
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 257
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 256
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 253
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 249
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 246
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 242
Druggable Targets in Pancreatic Adenocarcinoma 240
Natural compounds for cancer treatment and prevention 232
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 231
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 227
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 215
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 201
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 197
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 185
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 182
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 167
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 164
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 154
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 146
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 143
Pharmacogenetics: Implementing personalized medicine 143
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 143
Cellular pharmacology of gemcitabine. 142
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 141
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 141
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 141
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 140
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 139
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 131
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 128
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 126
Chronic inflammation in urothelial bladder cancer 126
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. 125
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 122
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 121
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 121
Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study 118
Prognostic factors in primary and iterative surgery of colorectal liver metastases 117
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 117
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 116
Postoperative chemotherapy in resected gastric cancer: results of a single center experience. 116
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 112
Size dependent biological profiles of PEGylated gold nanorods 112
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 109
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 108
Pharmacological strategies for overcoming multidrug resistance. 107
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 107
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 107
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 106
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) 106
Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. 105
Role of ATP-binding cassette transporters in cancer initiation and progression 103
Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies. 100
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 99
In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment 99
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 97
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 97
The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. 97
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 96
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 96
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 95
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. 95
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma 95
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 95
Does surgical prophylaxis with teicoplanin constitute a therapeutic advance? 94
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. 94
Genomic and genetic alterations influence the progression of gastric cancer 93
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 92
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 92
Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT 91
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 89
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 89
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer 88
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. 88
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients. 87
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 87
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 87
Next-Generation Sequencing to Identify Rare Variants Related to FL-Toxicity 86
Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (PTS) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT. 85
Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale 84
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 82
Thymidylate Synthase (TS) mRNA expression and TS gene promoter polymorphism in primary colorectal cancer (CRC) patients (PTS) receiving post-operative fluorouracil (5-FU)-based chemotherapy (CT) 82
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 81
Sequence-dependent interactions between oxaliplatin and 5-fluorouracil in human colon carcinoma cell lines 81
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 81
HLA-G 3’UTR +2960 14-bp INDEL (Ins/Del) polymorphism is associated to improved DFS of stage II-III CRC patients. 81
Plasma and intracellular pharmacokinetic (PK) study of prolonged infusion (PI) of gemcitabine (G) in combination with bolus cisplatin (C), in advanced nonsmall cell lung cancer: Preliminary results 80
In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles 79
Administering gemcitabine as fixed-dose-rate infusion in combination with cisplatin, potentially effective target plasma concentrations are achieved in patients with advanced non-small cell lung cancer 79
The clinical role of PIK3CA mutations in colorectal cancer 77
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 77
Totale 14.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.407
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.407
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.336 0 0 0 0 0 0 284 316 255 184 236 61
2020/20211.826 140 184 70 208 120 196 115 132 186 255 91 129
2021/20221.089 28 116 62 47 30 69 40 101 65 49 153 329
2022/20233.103 276 533 119 279 219 560 372 183 379 15 71 97
2023/20241.225 50 116 193 37 91 142 99 266 30 78 64 59
2024/20255.833 312 829 501 1.152 2.076 960 3 0 0 0 0 0
Totale 18.358